Related Experiment Video
Updated: Jul 18, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Hepatitis C virus re-infection: new perspectives
Martin F Sprinzl1, Gerd Otto, Peter R Galle
1Department of Internal Medicine, Johannes Gutenberg University Mainz, Mainz, Germany.
Insights
Hepatitis C virus (HCV) re-infection impacts liver transplant outcomes. Current antiviral treatments show low efficacy, necessitating further research for improved patient prognosis after transplantation.
Area of Science:
- Hepatology
- Transplantation Immunology
- Virology
Background:
- Hepatitis C virus (HCV) re-infection is a major determinant of outcomes in liver transplant recipients.
- Recurrent HCV cirrhosis leads to graft loss and is the primary cause of death post-transplantation.
- Despite advances, the prognosis for HCV-infected patients undergoing liver transplantation has not improved in 20 years.
Purpose of the Study:
- To highlight the critical role of HCV re-infection in liver transplant outcomes.
- To discuss the challenges and limitations of current antiviral therapies for HCV recurrence.
- To emphasize the need for optimized treatment strategies and further clinical trials.
Main Methods:
- Review of existing literature on HCV re-infection post-liver transplantation.
- Analysis of prognostic factors, including donor age and immunosuppression intensity.
- Evaluation of the efficacy and toxicity of current antiviral treatments (interferon and ribavirin).
Main Results:
- HCV re-infection significantly worsens graft survival and patient prognosis.
- Increased liver donor age and intensified immunosuppression are linked to poorer outcomes.
- Current antiviral regimens achieve low sustained viral response rates (10-30%).
Conclusions:
- Effective management of HCV re-infection is crucial for liver transplant success.
- Existing antiviral therapies are limited by toxicity and low efficacy.
- Prospective trials are essential to determine optimal antiviral treatment timing and regimens for transplant patients.
Abstract:
Hepatitis C virus (HCV) re-infection of the liver graft has been recognized to be one of the most important factors that determines prognosis and outcome after liver transplantation in HCV-positive patients. Graft loss due to recurrent HCV re-cirrhosis and subsequent hepatic decompensation, which is the predominant cause of death among transplant recipients, reflects the prognostic significance of HCV re-infection. Despite better overall outcome after liver transplantation, the prognosis of HCV-infected patients has not improved during the last two decades. Recent data suggest that increased liver donor age and intensified immunosuppression of transplant patients are the most important contributors to this situation. Other prognostic factors need further confirmation to stratify risk constellations. As HCV cirrhosis has also become the leading indication for orthotopic liver transplantation, the therapeutic management of HCV re-infection is a central issue of liver transplantation. The antiviral approaches based on interferon (IFN) alpha and ribavirin combinations are still hampered by high toxicity and low efficacy. Sustained viral response rates are still as low as approximately 10-30% and further prospective clinical trials are mandatory to identify the best time point and schedule of antiviral treatment in transplant patients.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Cytomegalovirus Disease
Viral Recombination
Retrovirus Life Cycles
Cirrhosis II: Pathophysiology
